Chemistry - Phthalates - Liquid

Liquid formulations and extracts require phthalate analysis yet solid material extraction methods prove unnecessarily complex - direct liquid analysis eliminates preparation steps while maintaining sensitivity below regulatory thresholds. Direct phthalate analysis in liquids eliminates extraction steps providing rapid quantification of these regulated compounds in liquid samples through GC-MS methodology. This streamlined approach achieves detection limits below regulatory thresholds minimizing sample preparation while maintaining sensitivity, enabling rapid screening of multiple samples, and reducing analysis costs through simplified methodology. Essential for analyzing extracts from medical devices testing leachable phthalate content under simulated use, monitoring phthalate levels in pharmaceutical preparations where plasticizer contamination compromises quality, and investigating contamination in liquid products requiring source identification. For device extracts representing patient exposure, direct analysis quantifies phthalates that migrate during simulated use, supports risk assessment calculating exposure from measured levels and contact duration, and validates materials as phthalate-free when results fall below detection limits. The GC-MS methodology provides definitive phthalate identification through mass spectral confirmation, accommodates various phthalate types from legacy to replacement plasticizers, and quantifies multiple phthalates simultaneously in single analysis. Manufacturing applications include quality control of process liquids ensuring phthalate-free status, investigation of unexpected contamination identifying sources, and validation of cleaning procedures demonstrating phthalate removal from equipment.

No.
1007021
Standard
Analyses category
Sample type
Liquid sample
Sample requirement (type)
Sterile or non sterile
Sample quantities
5 ml
Equipment
GC-MS
Lead Time Standard (Days)
10
Lead Time Express (Days)
5
Lead Time Super Express (Days)
2
Accredited
Yes
Test facility
In House
Add this test to cart to request an offer.

Do you need some help?

Other similar tests

EPA 8270, EPA 525
Chemistry - Phthalates - Solid

Phthalate plasticizers provide flexibility in medical devices yet these endocrine disruptors accumulate in patients through chronic exposure - particularly concerning for neonatal and pediatric populations where developmental impacts prove most severe. Phthalate analysis by GC-MS detects 13 regulated compounds following global restrictions on these endocrine disruptors, with extraction techniques liberating phthalates from polymer matrices for accurate quantification. The methodology addresses REACH, CPSIA, and medical device regulations restricting phthalate use particularly in pediatric applications, with sensitive detection ensuring compliance with increasingly stringent limits. Critical for PVC-based devices where alternative plasticizers require validation demonstrating acceptable toxicological profiles, pediatric devices with stringent phthalate limits protecting vulnerable populations from developmental harm, and demonstrating compliance with expanding global restrictions targeting additional phthalate compounds. Quality control applications include raw material verification ensuring suppliers provide phthalate-free or compliant materials, monitoring plasticizer migration from packaging where phthalates transfer from PVC packaging into contained devices, and validation testing alternative plasticizers confirming phthalate-free formulations. For medical devices with extended patient contact particularly neonatal intensive care equipment, phthalate testing validates that cumulative exposure remains within safe limits, alternative plasticizers replacing restricted phthalates don't introduce equally concerning compounds, and processing modifications reduce phthalate content in legacy products. The testing accommodates various phthalate types from traditional DEHP through replacement phthalates now facing restrictions, quantifies both free phthalates and bound plasticizers that migrate during use, and supports risk assessment calculating patient exposure from device contact duration and phthalate levels. Manufacturing investigations use phthalate testing identifying contamination sources when screening detects unexpected levels, validating cleaning procedures remove phthalate residues from equipment, and demonstrating formulation changes successfully eliminate restricted phthalates while maintaining material performance.